OBJECTIVES: The objective of this study is to identify, describe, analyze & compare the different types of innovative models used for paying for gene therapies with their possible limitations and advantages

METHODS: A literature search in the Bibliographic databases, the Internet and government/HTA organization websites was performed and resulted in the identification of relevant publications. The collected data was analyzed and synthesized. The findings are included in the subsequent analysis.

RESULTS:

Different innovative payment models were identified and proposed, such as pay for performance, annuity/installments, consumer mortgage, direct payment/distribution, expanded risk pools, re-insurance etc. However, a single payment model may not be sufficient and applicable to different health systems. In some cases even a combination of models will be required. Each solution must be tailored to the local environment, in which it will be applied and in accordance with the specifics of the health system.

CONCLUSIONS: Innovative payment models are needed, securing access to gene therapies and addressing the costs associated with their application, the uncertainty regarding long-term effectiveness and the value measurement of the therapies.